Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOST | Q9BQB4 | 1/20 | 0.77 |
| ▸ | FPGS | Q05932 | 2/20 | 0.69 |
| ▸ | ATIC | P31939 | 2/20 | 0.59 |
| ▸ | GART | P22102 | 4/20 | 0.57 |
| ▸ | DHFR | P00374 | 2/20 | 0.57 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.53 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TYMS | P04818 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofolate SCHEMBL4535490 | 0.99 | SOST (0.78) | SOSTFPGSATICGARTDHFR | |
| Tetrahydrofolate SCHEMBL15263902 | 0.99 | SOST (0.78) | SOSTFPGSATICGARTDHFR | |
| Tetrahydrofolate SCHEMBL21194977 | 0.99 | SOST (0.78) | SOSTFPGSATICGARTDHFR | |
| Tetrahydrofolate SCHEMBL8031 | 0.99 | SOST (0.78) | SOSTFPGSATICGARTDHFR | |
| Tetrahydrofolate SCHEMBL159230 | 0.99 | SOST (0.78) | SOSTFPGSATICGARTDHFR | |
| Tetrahydrofolate SCHEMBL6880950 | 0.99 | SOST (0.78) | SOSTFPGSATICGARTDHFR | |
| Tetrahydrofolate SCHEMBL82453 | 0.99 | SOST (0.78) | SOSTFPGSATICGARTDHFR | |
| Tetrahydrofolate SCHEMBL3445556 | 0.98 | SOST (0.77) | SOSTFPGSATICGARTDHFR | |
| Tetrahydrofolate SCHEMBL21248600 | 0.98 | SOST (0.77) | SOSTFPGSATICGARTDHFR | |
| Tetrahydrofolate SCHEMBL19376762 | 0.98 | SOST (0.77) | SOSTFPGSATICGARTDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112121048-A | Quinolines for the combined treatment of esophageal cancer | 正大天晴药业集团股份有限公司 | 2020-12-25 | — | — | CN | claimed |
| CN-111773388-A | Combined application of A-nor-5 alpha androstane compound medicine and anticancer medicine | 上海奥奇医药科技有限公司 | 2020-10-16 | — | — | CN | claimed |
| WO-2020199973-A1 | COMBINED USE OF A-NOR-5α ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG | 上海奥奇医药科技有限公司 | 2020-10-08 | — | — | WO | claimed |
| CN-111635405-A | Production process of calcium tetrahydrofolate preparation | 无锡紫杉药业有限公司 | 2020-09-08 | — | — | CN | claimed |
| CN-103450202-B | Method for reacting L-5-methyltetrahydrofolic acid with organic base to form salt | NANJING RHINE PHARM TECHNOLOGY INC | 2015-07-01 | — | — | CN | claimed |
| CN-103664945-A | Preparation method of L-5-methyl tetrahydrofolate amino acid salt | NANJING RHINE PHARM TECHNOLOGY INC | 2014-03-26 | — | — | CN | claimed |
| CN-103450202-A | Method for reacting L-5-methyltetrahydrofolic acid with organic base to form salt | NANJING RHINE PHARM TECHNOLOGY INC | 2013-12-18 | — | — | CN | claimed |
| US-20240238271-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | SHANGHAI JUNCELL THERAPEUTICS CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-4252754-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | Shanghai Juncell Therapeutics Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| CN-116761606-A | Pharmaceutical composition for enhancing cell killing and application thereof | 上海君赛生物科技有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-111773388-B | Combined application of A-nor-5 alpha androstane compound medicine and anticancer medicine | 上海奥奇医药科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-115414384-A | Prevention of pulmonary recurrence of cancer with cisplatin lipid complexes | 埃莱森制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-110357886-B | Methotrexate hapten and complete antigen as well as preparation method and application thereof | 浙江准策生物技术有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20170273984-A1 | COMPOSITION COMPRISING (6S)-5-METHYL TETRAHYDROFOLIC ACID OR SALT THEREOF, AND PREPARATION AND USE THEREOF | LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| CN-103664945-B | The preparation method of L-5-methyl tetrahydrofolate amino acid salts | Laiyin Medicines Tech Co., Ltd., Nanjing (CN) | 2016-01-20 | — | — | CN | disclosed |
| CN-103450202-B | Method for reacting L-5-methyltetrahydrofolic acid with organic base to form salt | NANJING RHINE PHARM TECHNOLOGY INC | 2015-07-01 | — | — | CN | disclosed |
| CN-103664945-A | Preparation method of L-5-methyl tetrahydrofolate amino acid salt | NANJING RHINE PHARM TECHNOLOGY INC | 2014-03-26 | — | — | CN | disclosed |
| CN-103664945-A | Preparation method of L-5-methyl tetrahydrofolate amino acid salt | NANJING RHINE PHARM TECHNOLOGY INC | 2014-03-26 | — | — | CN | disclosed |
| CN-103450202-A | Method for reacting L-5-methyltetrahydrofolic acid with organic base to form salt | NANJING RHINE PHARM TECHNOLOGY INC | 2013-12-18 | — | — | CN | disclosed |
| JP-2000136135-A | COMPOSITION USING OPTICALLY ACTIVE COMPOUND | UNIV STRATHCLYDE | 2000-05-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238271-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | CTSA, GZMB, PRF1 | SOST 4477/4885FPGS 1579/4885ATIC 3094/4885 |
| US-20170273984-A1 | COMPOSITION COMPRISING (6S)-5-METHYL TETRAHYDROFOLIC ACID OR SALT THEREOF, AND PREPARATION AND USE THEREOF | BHMT2, DHPS, MAT2A | SOST 3038/4885FPGS 467/4885ATIC 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.